In the first EPIQ randomized controlled trial, 12 sites participated and targeted QI in one of two areas – Nosocomial Infection (NI) or Bronchopulmonary Disease (BPD). The targeted outcomes were significantly reduced, particularly in comparison to non-participating sites.